Immunomodulation: a new horizon for medical treatment of heart failure (Q41252862)

28 September 2017

1 reference

title

Immunomodulation: a new horizon for medical treatment of heart failure (English)

1 reference

28 September 2017

0 references

Sasayama S

1

1 reference

28 September 2017

Matsumori A

2

1 reference

28 September 2017

Matoba Y

3

1 reference

28 September 2017

Matsui S

4

1 reference

28 September 2017

Yamada T

5

1 reference

28 September 2017

Shioi T

6

1 reference

28 September 2017

Sato Y

7

1 reference

28 September 2017

Doyama K

8

1 reference

28 September 2017

Kishimoto C

9

1 reference

28 September 2017

publication date

1 December 1996

1 reference

Journal of Cardiac Failure

28 September 2017

published in

1 reference

28 September 2017

volume

2

1 reference

28 September 2017

issue

4 Suppl

1 reference

28 September 2017

page(s)

S287-94

1 reference

Viral infection and the pathogenesis of dilated cardiomyopathy

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

A case of biopsy-proven myocarditis progressing to autopsy-proven dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Routine use of mu-antibody-capture ELISA for the serological diagnosis of Coxsackie B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Cardiac persistence of cardioviral RNA detected by polymerase chain reaction in a murine model of dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Dilated Cardiomyopathy Associated With Hepatitis C Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Mechanisms of immune-mediated myocyte injury

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Increased circulating cytokines in patients with myocarditis and cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Correlation with disease severity and cardiac autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Negative inotropic effects of cytokines on the heart mediated by nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

A new method for assessment of cultured cardiac myocyte contractility detects immune factor-mediated inhibition of beta-adrenergic responses

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Antibody-mediated imbalance of myocardial energy metabolism. A causal factor of cardiac failure?

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

What do the newer inotropic drugs have to offer?

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

Immune modulation of cardiac function: a new frontier

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2896%2980089-3

7 January 2021

10.1016/S1071-9164(96)80089-3

Identifiers

DOI

1 reference

28 September 2017

1 reference